- Home
- YCY vs UNCY Comparison
YCY vs UNCY Comparison
Compare YCY & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | YCY | UNCY |
|---|---|---|
| Founded | 2025 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.0M | 145.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | YCY | UNCY |
|---|---|---|
| Price | $10.19 | $5.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 8.1K | ★ 2.6M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $582.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $3.72 |
| 52 Week High | $10.24 | $8.74 |
Technical Indicators
Market Signals| Indicator | YCY | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 58.09 | 41.43 |
| Support Level | $9.95 | $4.18 |
| Resistance Level | N/A | $6.50 |
| Average True Range (ATR) | 0.00 | 0.49 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 50.00 | 34.71 |
Price Performance
Historical ComparisonAbout YCY AA Mission Acquisition Corp. II Class A Ordinary Shares
AA Mission Acquisition Corp II is a blank check company formed for the purpose of effectuating a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.